The 25 analysts offering 12-month price forecasts for Novo Nordisk A/S have a median target of 127.17, with a high estimate of 149.40 and a low estimate of 75.50. The median estimate represents a +1.36% increase from the last price of 125.47.
The current consensus among 28 polled investment analysts is to Buy stock in Novo Nordisk A/S. This rating has held steady since November, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $0.80
Reporting Date Feb 01
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.